Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease

References

• Thom T, Haase N, Rosamond W et al. Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation113(6), e85–e151 (2006).
   PubMed Web of Science ®Google Scholar
• Khavkin T. Nikolai Nikolaevich Anitschkow. Beitr. Pathol.156(4), 301–312 (1975).
   PubMedGoogle Scholar
• Vance DE, Van den Bosch H. Cholesterol in the year 2000. Biochim. Biophys. Acta1529(1–3), 1–8 (2000).
   PubMedGoogle Scholar
• Soloff LA. Intermediate lipoproteins, atherosclerosis, and Gofman. Circulation97(7), 708 (1998).
   PubMedGoogle Scholar
• Endo A. The origin of the statins. Atheroscler. Suppl.5(3), 125–130 (2004).
   PubMed Web of Science ®Google Scholar
• Topol EJ. Intensive statin therapy – a sea change in cardiovascular prevention. N. Engl. J. Med.350, 1562–1564 (2004).
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344(8934), 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med.333, 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA279, 1615–1622 (1998).
   PubMed Web of Science ®Google Scholar
• Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med.339, 1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Arch. Int. Med.148, 36–69 (1988).
   PubMed Web of Science ®Google Scholar
• Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA285(19), 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur. Heart J.20(10), 725–741 (1999).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med.350(15), 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol.44(3), 720–732 (2004).
   PubMed Web of Science ®Google Scholar
• Shah PK. Low-density lipoprotein lowering and atherosclerosis progression: does more mean less? Circulation106(16), 2039–2040 (2002).
   PubMed Web of Science ®Google Scholar
• Forrester JS, Makkar R, Shah PK. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation111(14), 1847–1854 (2005).
   PubMedGoogle Scholar
• LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med.352(14), 1425–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Wiviott SW, Cannon CP, Morrow DA et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J. Am. Coll. Cardiol.46, 1411–1416 (2005).
   PubMed Web of Science ®Google Scholar
• Ferdinand KC. Rosuvastatin: a risk-benefit assessment for intensive lipid lowering. Expert Opin. Pharmacother.6(11), 1897–1910 (2005).
   PubMed Web of Science ®Google Scholar
• McKenney JM. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am. J. Cardiol.96(4A), 60E–66E (2005).
   PubMed Web of Science ®Google Scholar
• Nezasa K, Higaki K Takeuchi M, Nakano M, Koike M. Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica33(4), 379–388 (2003).
   PubMed Web of Science ®Google Scholar
• Carbonell T, Freire E. Binding thermodynamics of statins to HMG-CoA reductase. Biochemistry44, 11741–11748 (2005).
   PubMed Web of Science ®Google Scholar
• Holdgate GA, Ward WH, McTaggert F. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem. Soc. Trans.31(Pt 3), 528–531 (2003).
   PubMed Web of Science ®Google Scholar
• Schaefer JR, Schweer H, Ikewaki K et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis144(1), 177–184 (1999).
   PubMed Web of Science ®Google Scholar
• Martin G, Duez H, Blanquart C et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J. Clin. Invest.107(11), 1423–1432 (2001).
   PubMed Web of Science ®Google Scholar
• Toth PP. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am. J. Cardiol.96(9A), 50K–58K (2005).
   PubMed Web of Science ®Google Scholar
• Simonson SG, Martin PD, Mitchell P et al. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur. J. Clin. Pharm.58(10), 669–675 (2003).
   PubMed Web of Science ®Google Scholar
• Martin PD, Dane AL, Nwose OM et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J. Clin. Pharmacol.42(10), 1116–1121 (2002).
   PubMed Web of Science ®Google Scholar
• Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br. J. Clin. Pharmacol.54(5), 472–477 (2002).
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sugiama Y. Pharmacokinetic and pharmacodynamic alterations of HMG-CoA reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther.112(1), 71–105 (2006).
   PubMed Web of Science ®Google Scholar
• McCormick AD, McKillop D, Butters CJ et al. ZD4522 – an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems. J. Clin. Pharmacol.40, 1055 (2000) (Abstract).
   Google Scholar
• Martin PD, Dane AL, Schneck DW et al. Disposition of a new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects. J. Clin. Pharmacol.40, 1056 (2006) (Abstract).
   Google Scholar
• Product information: Crestor®, rosuvastatin calcium tablets. Astra Zeneca Pharmaceuticals, DE, USA (PI issued 8/2003) reviewed 8/2003.
   Google Scholar
• Simonson SG, Martin PD, Mitchell PD et al. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur. J. Clin. Pharmacol.58(10), 669–675 (2003).
   PubMed Web of Science ®Google Scholar
• Sekino H, Onishi T. Phase I study of ZD4522 (rosuvastatin), a new HMG-CoA reductase inhibitor – evaluation of tolerance and pharmacokinetics in healthy adult male volunteers after single and repeated oral administration. J. Clin. Ther. Med.21, 187–203 (2005).
   Google Scholar
• Lee E, Ryan S, Birmingham B et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther.78(4), 330–341 (2005).
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Martin PD, Dane AL et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther.73(4), 322–329 (2003).
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Martin PD, Dane AL et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br. J. Clin. Pharmacol.55(1), 94–99 (2003).
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Martin PD, Dane AL et al. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur. J. Clin. Pharmacol.59(1), 51–56 (2003).
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Martin PD, Dane AL et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur. J. Clin. Pharmacol.58(8), 527–531 (2002).
   PubMed Web of Science ®Google Scholar
• Simonson G, Raza A, Martin PD et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharm. Therap.76(2), 167–177 (2004).
   PubMed Web of Science ®Google Scholar
• Simonson SG, Martin PD, Mitchell PD et al. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J. Clin. Pharm.45(8), 927–934 (2005).
   PubMed Web of Science ®Google Scholar
• Redman AR. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy21(2), 235–242 (2001).
   PubMed Web of Science ®Google Scholar
• Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann. Pharmacother.35, 908–917 (2001).
   PubMed Web of Science ®Google Scholar
• Bellosta S. Safety of statins. Circulation109, 50–57 (2004).
   Web of Science ®Google Scholar
• Prueksaritanont T, Tang C, Qiu Y et al. Effect of fibrates on metabolism of statins in humans hepatocytes. Drug Metab. Dispos.30, 1280–1287 (2002).
   PubMed Web of Science ®Google Scholar
• Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am. J. Cardiol.81(3), 368–369 (1998).
   PubMed Web of Science ®Google Scholar
• Schneck DW, Birmingham BK, Zalikowski JA et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther.75(5), 455–463 (2004).
   PubMed Web of Science ®Google Scholar
• McKenney JM. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am. J. Health Syst. Pharm.62(10), 1033–1047 (2005).
   PubMed Web of Science ®Google Scholar
• Martin P, Dane A, Schneck D, Warwick M. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin. Therapeut.25(2), 459–471 (2003).
   PubMed Web of Science ®Google Scholar
• Brewer HB. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. J. Cardiol.92(4B), 23K–29K (2003).
   PubMed Web of Science ®Google Scholar
• Olsson AG, Istad H, Luurila O et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am. Heart J.144(6), 1044–1051 (2002).
   PubMed Web of Science ®Google Scholar
• Schneck DW, Knopp RH, Ballantyne CM et al. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am. J. Cardiol.91(1), 33–41 (2003).
   PubMed Web of Science ®Google Scholar
• Schuster H. The GALAXY program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev. Cardiovasc. Ther.5(2), 177–193 (2006).
   Google Scholar
• Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol.92(2), 152–160 (2003).
   PubMed Web of Science ®Google Scholar
• Brown WV, Bays HE, Hassman DR et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am. Heart J.144(6), 1036–1043 (2002).
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Leiter LA, Kallend D. A review of the efficacy of rosuvastatin in patients with Type 2 diabetes. Int. J. Clin. Pract. Suppl.143, 30–40 (2004).
   Google Scholar
• Krum H, Tonkin A et al. The rosuvastatin impact on ventricular remodelling cytokines and neurohormones (UNIVERSE) study. J. Am. Coll. Cardiol.26(47), 61A–62A (2006) (Abstract).
   Google Scholar
• Raina A, Pickering T, Shimbo D. Statin use in heart failure – a cause for concern? Am. Heart J.152(1), 39–49 (2006).
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Clark LT, Watson KE et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am. J. Cardiol.97(2), 229–235 (2006).
   PubMed Web of Science ®Google Scholar
• Llorett R, Haffner S, Ycas J, Stein M et al. for the STARSHIP Study Group. Lipid-lowering results from the first large-scale trial of statin therap in Hispanic-American patients with hypercholesterolemia: STARSHIP. J. Am. Coll. Cardiol.26(47), 349A–350A (2006) (Abstract).
   Google Scholar
• Deedwania P, Gupta M, Stein M et al. First large randomized trial of a statin therapy in South Asian patients at risk for coronary heart disease: the IRIS trial. Atheroscler. Suppl.206(7), 161 (2006).
   Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet357(9256), 577–581 (2001).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Kent SM, Flaherty PJ et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation106(16), 2055–2060 (2002).
   PubMed Web of Science ®Google Scholar
• Crouse JR, Grobbee DE, O’leary DH et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis – the rationale and methodology of the METEOR study. Cardiovasc. Drugs Ther.18(3), 231–238 (2004).
   PubMed Web of Science ®Google Scholar
• Hatsukami T, Zhao XQ, Kraiss LW et al. Assessment of rosuvastatin treatment on carotid atherosclerosis in moderate hypercholesterolemic subjects using magnetic resonance imaging. Eur. Heart J.26, 626 (2005).
   Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA291(9), 1071–1080 (2004).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA295(13), 1556–1565 (2006).
   PubMed Web of Science ®Google Scholar
• Blumenthal RS, Kapur NK. Can a potent statin actually regress coronary atherosclerosis? JAMA295(13), 1583–1584 (2006).
   PubMedGoogle Scholar
• Ridker PM; JUPITER study group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation108(19), 2292–2297 (2003).
   PubMed Web of Science ®Google Scholar
• Fellstrom B, Zannad F, Schmieder R et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study. Curr. Control Trials Cardiovasc. Med.6(1), 9 (2005).
   PubMedGoogle Scholar
• Kjekshus J, Dunselman P, Blideskog M et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur. J. Heart Fail.7(6), 1059–1069 (2005).
   PubMed Web of Science ®Google Scholar
• Vidt DG, Harris S, McTaggart F et al. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am. J. Cardiol.97(11), 1602–1166 (2006).
   PubMed Web of Science ®Google Scholar
• McAfee AT, Ming EE, Seeger JD et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol. Drug Saf.15, 444–453 (2006).
   PubMed Web of Science ®Google Scholar
• Grundy SM. The issue of statin safety: where do we stand? Circulation111(23), 3016–3019 (2005).
   PubMed Web of Science ®Google Scholar
• Goettsch WG, Heintjes EM, Kastelein JJ et al. Results from a rosuvastatin historical cohort study in more than 45 000 Dutch statin users, a PHARMO study. Pharmacoepidemiol. Drug Saf.15(7), 435–443 (2006).
   PubMed Web of Science ®Google Scholar
• Alsheikh-Ali AA, Ambrose MS, Kuvin JT et al. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation111(23), 3051–3057 (2005).
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation79(1), 8–15 (1989).
   PubMed Web of Science ®Google Scholar
• Castelli WP, Anderson K, Wilson PW et al. Lipids and risk of coronary heart disease. The Framingham Study. Ann. Epidemiol.2(1–2), 23–28 (1992).
   PubMedGoogle Scholar
• Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. 1982. JAMA277(7), 582–594 (1997).
   PubMedGoogle Scholar
• Jones P. 2006 International Symposium on Atherosclerosis June 18–22, Rome, Italy (2006).
   Google Scholar
• Brousseau ME, Schaefer EJ, Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med.350(15), 1505–1515 (2004).
   PubMed Web of Science ®Google Scholar
• Stelenhoef AG, Ballantyne CM, Sarti C et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur. Heart J.26(24), 2664–2672 (2005).
   PubMedGoogle Scholar
• Strandberg TE, Feely J, Sigurdsson EL. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clin. Ther.26(11), 1821–1833 (2004).
   PubMed Web of Science ®Google Scholar
• Faergeman O, Sosef F, Duffield E. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in high-risk patients: results from the ECLIPSE Study. Atheroscler. Suppl.7, 580 (2006).
   Google Scholar
• Pitt B, Loscalzo J, Ycas J, Raichlen J. Acute coronary syndromes do not lower lipid levels. J. Am. Coll. Cardiol.47(Suppl. 1), 323A (2006).
   Google Scholar
• Schuster H, Barter PJ, Stender S et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY I) study. Am. Heart J.147, 705–712 (2004).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bertolami M, Hernandez Garcia HR et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am. Heart J.151, 975.e1–e9 (2006).
   PubMed Web of Science ®Google Scholar
• Willich S, Müller-Nordhorn J, Sonntag F. Effects of a twelve months rosuvastatin treatment plus additional care (drug intake adherence and lifestyle enhancing initiatives) compared to rosuvastatin treatment alone on long-term disease-related costs in patients with an indication for statin treatment according to the joint European guidelines. Am. Heart J.148(6), 1060–1067 (2004).
   PubMed Web of Science ®Google Scholar
• Leiter LA, Palmer M, Kallend D. Rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolaemia: early results of the POLARIS study. Atheroscler. Suppl.6, 113 (2005).
   Google Scholar
• Clearfield M, Kallend D, Palmer M. Efficacy and safety of rosuvastatin 10 mg versus atorvastatin 20 mg: results of the PULSAR study. Atheroscler. Suppl.6, 104 (2005).
   Google Scholar
• Berne C, Siewert-Delle A, and URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with Type 2 diabetes mellitus: results from the URANUS study. Cardiovasc. Diabetol.5, 4–7 (2005).
   Google Scholar